Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Umeclidinium and Vilanterol Combination in COPD
NCT01039675Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2010
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GSK573719/GW642444 with Placebo (2 arms). Primary endpoint: Change From Baseline in Weighted Mean Pulse Rate Over 0 to 6 Hours Post-dose at Day 28. Started Jan 2010; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01039675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01039675.